{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:02:53Z","timestamp":1791478973631,"version":"4.3.4"},"reference-count":97,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1168194"],"award-info":[{"award-number":["APP1168194"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001232","name":"Royal Australasian College of Physicians","doi-asserted-by":"publisher","award":["APP1168194"],"award-info":[{"award-number":["APP1168194"]}],"id":[{"id":"10.13039\/501100001232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>The incidence of infectious complications, compared with the general population and the pre-transplant status of the recipient, increases substantially following kidney transplantation, causing significant morbidity and mortality. The potent immunosuppressive therapy given to prevent graft rejection in kidney transplant recipients results in an increased susceptibility to a wide range of opportunistic infections including bacterial, viral and fungal infections. Over the last five years, several advances have occurred that may have changed the burden of infectious complications in kidney transplant recipients. Due to the availability of direct-acting antivirals to manage donor-derived hepatitis C infection, this has opened the way for donors with hepatitis C infection to be considered in the donation process. In addition, there have been the development of medications targeting the growing burden of resistant cytomegalovirus, as well as the discovery of the potentially important role of the gastrointestinal microbiota in the pathogenesis of post-transplant infection. In this narrative review, we will discuss these three advances and their potential implications for clinical practice.<\/jats:p>","DOI":"10.3390\/medicina55100672","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T10:54:58Z","timestamp":1570186498000},"page":"672","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Infectious Complications Following Kidney Transplantation\u2014A Focus on Hepatitis C Infection, Cytomegalovirus Infection and Novel Developments in the Gut Microbiota"],"prefix":"10.3390","volume":"55","author":[{"given":"Samuel","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia"},{"name":"Australasian Kidney Trials Network, The University of Queensland, Brisbane, QLD 4102, Australia"},{"name":"Translational Research Institute, Brisbane, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M","family":"Isbel","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia"},{"name":"Australasian Kidney Trials Network, The University of Queensland, Brisbane, QLD 4102, Australia"},{"name":"Translational Research Institute, Brisbane, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel M","family":"Hawley","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia"},{"name":"Australasian Kidney Trials Network, The University of Queensland, Brisbane, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott B","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia"},{"name":"Australasian Kidney Trials Network, The University of Queensland, Brisbane, QLD 4102, Australia"},{"name":"Translational Research Institute, Brisbane, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4479-1284","authenticated-orcid":false,"given":"Katrina L","family":"Campbell","sequence":"additional","affiliation":[{"name":"Australasian Kidney Trials Network, The University of Queensland, Brisbane, QLD 4102, Australia"},{"name":"Centre for Applied Health Economics, Menzies Research Institute, Griffith University, Brisbane, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Morrison","sequence":"additional","affiliation":[{"name":"The University of Queensland Diamantina Institute, Faculty of Medicine, University of Queensland, Woolloongabba, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross S","family":"Francis","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia"},{"name":"Australasian Kidney Trials Network, The University of Queensland, Brisbane, QLD 4102, Australia"},{"name":"Translational Research Institute, Brisbane, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Geoffrey","family":"Playford","sequence":"additional","affiliation":[{"name":"Australasian Kidney Trials Network, The University of Queensland, Brisbane, QLD 4102, Australia"},{"name":"Infection Management Services, Department of Microbiology, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-3460","authenticated-orcid":false,"given":"David W","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia"},{"name":"Australasian Kidney Trials Network, The University of Queensland, Brisbane, QLD 4102, Australia"},{"name":"Translational Research Institute, Brisbane, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/ajt.14208","article-title":"Infection in organ transplantation","volume":"17","author":"Fishman","year":"2017","journal-title":"Am. J. Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2215\/CJN.11511017","article-title":"Secular Trends in Infection-Related Mortality after Kidney Transplantation","volume":"13","author":"Kinnunen","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.amjsurg.2015.07.033","article-title":"Hepatitis C status and infectious complications in the surgical intensive care unit: A retrospective analysis of 1,941 consecutive patients","volume":"211","author":"Kueht","year":"2016","journal-title":"Am. J. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMra1213651","article-title":"Current and Future Therapies for Hepatitis C Virus Infection","volume":"368","author":"Liang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2019.01.011","article-title":"Clinical Development of Letermovir and Maribavir: Overview of Human Cytomegalovirus Drug Resistance","volume":"163","author":"Piret","year":"2019","journal-title":"Antiviral Res."},{"key":"ref_6","first-page":"697","article-title":"Gut microbial community structure and complications following kidney transplantation: A pilot study","volume":"98","author":"Lee","year":"2014","journal-title":"Transplantation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/ajt.14974","article-title":"Gut microbiota dysbiosis and diarrhea in kidney transplant recipients","volume":"19","author":"Lee","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lee, J., Muthukumar, T., Dadhania, D., Taur, Y., Jenq, R., Toussaint, N., Ling, L., Pamer, E., and Suthanthiran, M. (2015). Gut Microbiota and Tacrolimus Dosing in Kidney Transplantation. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122399"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1600-6143.2011.03493.x","article-title":"An update on donor-derived disease transmission in organ transplantation","volume":"11","author":"Ison","year":"2011","journal-title":"Am. J. Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e12851","DOI":"10.1111\/tid.12851","article-title":"Unexpected donor-derived infectious transmissions by kidney transplantation: A systematic review","volume":"20","author":"Shingde","year":"2018","journal-title":"Transpl. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/ajt.12095","article-title":"Donor-Derived Infections in Solid Organ Transplantation","volume":"13","author":"Ison","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1097\/TP.0b013e318236cd02","article-title":"Uniform Definitions for Donor-Derived Infectious Disease Transmissions in Solid Organ Transplantation","volume":"92","author":"Garzoni","year":"2011","journal-title":"Transplantation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1111\/ajt.14381","article-title":"The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation","volume":"17","author":"Levitsky","year":"2017","journal-title":"Am. J. Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1111\/ajt.13971","article-title":"Improving Organ Utilization to Help Overcome the Tragedies of the Opioid Epidemic","volume":"16","author":"Goldberg","year":"2016","journal-title":"Am. J. Transplant."},{"key":"ref_15","first-page":"4674560","article-title":"Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients","volume":"2019","author":"Armando","year":"2019","journal-title":"BioMed Res. Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/ajt.13976","article-title":"Changes in Utilization and Discard of Hepatitis C\u2013Infected Donor Livers in the Recent Era","volume":"17","author":"Bowring","year":"2017","journal-title":"Am. J. Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/hep.29704","article-title":"Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients","volume":"67","author":"Bari","year":"2018","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1097\/TP.0000000000002034","article-title":"Detection of hepatitis C antibodies without viral transmission in hepatitis C-negative recipients receiving kidneys from hepatitis C-positive donors treated with direct-acting antiviral therapy","volume":"102","author":"Agarwal","year":"2018","journal-title":"Transplantation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1111\/ajt.15031","article-title":"Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV viremia","volume":"18","author":"Volk","year":"2018","journal-title":"Am. J. Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1111\/ajt.15415","article-title":"Early emergence of anti-HCV antibody implicates donor origin in recipients of an HCV-infected organ","volume":"19","author":"Porrett","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"702","DOI":"10.7326\/M17-2451","article-title":"The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study","volume":"168","author":"Durand","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/TP.0000000000002033","article-title":"Use of organs from hepatitis C virus-positive donors for uninfected recipients: A potential cost-effective approach to save lives?","volume":"102","author":"Trotter","year":"2018","journal-title":"Transplantation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1097\/TXD.0000000000000852","article-title":"Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission","volume":"5","author":"White","year":"2019","journal-title":"Transplant. Direct"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1515\/jtim-2017-0007","article-title":"Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction","volume":"5","author":"Geddawy","year":"2017","journal-title":"J. Transl. Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"AASLD\/IDSA HCV Guidance Panel (2015). Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology, 62, 932\u2013954.","DOI":"10.1002\/hep.27950"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/j.1600-6143.2006.01374.x","article-title":"Acute Renal Allograft Rejection Following Pegylated IFN-\u03b1 Treatment for Chronic HCV in a Repeat Allograft Recipient on Hemodialysis: A Case Report","volume":"6","author":"Carbognin","year":"2006","journal-title":"Am. J. Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: A prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"k1382","DOI":"10.1136\/bmj.k1382","article-title":"Do direct acting antivirals cure chronic hepatitis C?","volume":"361","author":"Jakobsen","year":"2018","journal-title":"BMJ"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMc1705221","article-title":"Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients","volume":"376","author":"Goldberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve-Month Outcomes After Transplant of Hepatitis C\u2013Infected Kidneys Into Uninfected Recipients: A Single-Group Trial","volume":"169","author":"Reese","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus\u2013Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial","volume":"168","author":"Durand","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa1812406","article-title":"Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients","volume":"380","author":"Woolley","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/ajt.15152","article-title":"Transplantation of HCV-infected organs into uninfected recipients: Advance with caution","volume":"19","author":"Wadei","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1164\/rccm.201712-2614LE","article-title":"Lung transplantation from hepatitis C viremic donors to uninfected recipients","volume":"197","author":"Abdelbasit","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.healun.2018.01.1293","article-title":"Early outcomes using hepatitis C\u2013positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies","volume":"37","author":"Schlendorf","year":"2018","journal-title":"J. Heart Lung Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/cid\/ciu012","article-title":"Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries","volume":"58","author":"Hill","year":"2014","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_37","unstructured":"(2019, August 17). The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03809533."},{"key":"ref_38","unstructured":"(2019, August 17). The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03819322."},{"key":"ref_39","unstructured":"(2019, August 17). Expanding the Pool in Orthotopic Heart Transplantation, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03222531."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1002\/hep.30540","article-title":"Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors","volume":"69","author":"Cotter","year":"2019","journal-title":"Hepatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1111\/ajt.14895","article-title":"The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes","volume":"18","author":"Axelrod","year":"2018","journal-title":"Am. J. Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.cgh.2017.08.020","article-title":"Improved outcomes in HCV patients following liver transplantation during the era of direct-acting antiviral agents","volume":"16","author":"Cholankeril","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.14929","article-title":"Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients","volume":"18","author":"Kadatz","year":"2018","journal-title":"Am. J. Transplant."},{"key":"ref_44","unstructured":"Centers for Disease Control and Prevention (2015, May 07). Core Elements of Hospital Antibiotic Stewardship Programs, Available online: https:\/\/www.cdc.gov\/antibiotic-use\/healthcare\/implementation\/core-elements.html."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1\u20136 hepatitis C virus\u2013infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","volume":"59","author":"Svarovskaia","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2147\/IDR.S169512","article-title":"Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus","volume":"11","author":"Tavares","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/tri.13393","article-title":"Impact of hepatitis C virus and direct acting antivirals on kidney recipients: A retrospective study","volume":"32","author":"Gendia","year":"2019","journal-title":"Transpl. Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.kint.2017.10.024","article-title":"Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient","volume":"93","author":"Chute","year":"2018","journal-title":"Kidney Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e2017","DOI":"10.1002\/rmv.2017","article-title":"Going beyond serology for stratifying the risk of CMV infection in transplant recipients","volume":"29","author":"Navarro","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/01.tp.0000230460.42558.b0","article-title":"The Natural Course of Cytomegalovirus Infection and Disease in Renal Transplant Recipients","volume":"82","author":"Hartmann","year":"2006","journal-title":"Transplantation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archopht.1996.01100140023002","article-title":"Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group","volume":"114","author":"Jabs","year":"1996","journal-title":"Arch. Ophthalmol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1086\/342385","article-title":"Ganciclovir-resistant cytomegalovirus in organ transplant recipients","volume":"35","author":"Limaye","year":"2002","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"ref_54","first-page":"1","article-title":"Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients","volume":"2","author":"Owers","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/AAC.49.3.873-883.2005","article-title":"Human Cytomegalovirus Resistance to Antiviral Drugs","volume":"49","author":"Gilbert","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1034\/j.1600-6143.2001.10403.x","article-title":"Cytomegalovirus (CMV) resistance to antivirals","volume":"1","author":"Drew","year":"2001","journal-title":"Am. J. Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/2010105815611811","article-title":"Resistant cytomegalovirus infection in renal transplant recipients","volume":"24","author":"Cherng","year":"2015","journal-title":"Proc. Singap. Healthc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In Vitro and In Vivo Activities of the Novel Anticytomegalovirus Compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.05908-11","article-title":"In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses","volume":"56","author":"Marschall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/tri.12225","article-title":"Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: Results of a Phase 2a study","volume":"27","author":"Stoelben","year":"2014","journal-title":"Transpl. Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","article-title":"First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246","volume":"11","author":"Kaul","year":"2011","journal-title":"Am. J. Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e02337-18","DOI":"10.1128\/AAC.02337-18","article-title":"Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis","volume":"63","author":"Turner","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.transproceed.2013.01.082","article-title":"Maribavir Use in Practice for Cytomegalovirus Infection in French Transplantation Centers","volume":"45","author":"Alain","year":"2013","journal-title":"Transplant. Proc."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1086\/653122","article-title":"Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir","volume":"202","author":"Strasfeld","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1111\/j.1600-6143.2012.04231.x","article-title":"Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: A randomized, double-blind, multicenter controlled trial","volume":"12","author":"Winston","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1084\/jem.20040613","article-title":"Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers","volume":"202","author":"Cobbold","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor","volume":"333","author":"Walter","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cid\/ciy549","article-title":"Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","volume":"68","author":"Smith","year":"2019","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1517\/14712598.2014.908847","article-title":"Therapeutic Strategies for Cytomegalovirus Infection in Haematopoietic Transplant Recipients: A Focused Update","volume":"14","author":"Sellar","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"16058","DOI":"10.1038\/mtm.2016.58","article-title":"Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients","volume":"3","author":"Dasari","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/MOG.0000000000000139","article-title":"The gut microbiome in health and in disease","volume":"31","author":"Shreiner","year":"2015","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nature06244","article-title":"The human microbiome project","volume":"449","author":"Turnbaugh","year":"2007","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrg3182","article-title":"The human microbiome: At the interface of health and disease","volume":"13","author":"Cho","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1348-0421.2004.tb03544.x","article-title":"Microbiota Composition of the Intestinal Mucosa: Association with Fecal Microbiota?","volume":"48","author":"Ouwehand","year":"2004","journal-title":"Microbiol. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2672.2005.02783.x","article-title":"Molecular characterization of the bacteria adherent to human colorectal mucosa","volume":"100","author":"Green","year":"2006","journal-title":"J. Appl. Microbiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1128\/AEM.68.7.3401-3407.2002","article-title":"Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces","volume":"68","author":"Zoetendal","year":"2002","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-16-2929","article-title":"The host microbiome regulates and maintains human health: A primer and perspective for non-microbiologists","volume":"77","author":"Thomas","year":"2017","journal-title":"Cancer Res."},{"key":"ref_83","first-page":"26191","article-title":"Dysbiosis of the gut microbiota in disease","volume":"26","author":"Carding","year":"2015","journal-title":"Microb. Ecol. Health Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/MIB.0000000000000750","article-title":"Current understanding of dysbiosis in disease in human and animal models","volume":"22","author":"DeGruttola","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Nataatmadja, M., Cho, Y., Campbell, K., and Johnson, D.W. (2017). The Roles of Indoxyl Sulphate and p-Cresyl Sulphate in Patients with Chronic Kidney Disease: A Review of Therapeutic Options. Chronic Kidney Disease-from Pathophysiology to Clinical Improvements, IntechOpen, Thomas Rath.","DOI":"10.5772\/intechopen.69325"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2215\/CJN.05240515","article-title":"Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial","volume":"11","author":"Rossi","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MNH.0000000000000262","article-title":"Current status of the microbiome in renal transplantation","volume":"25","author":"Ahmad","year":"2016","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/tri.13159","article-title":"Pancreas preservation fluid microbial contamination is associated with poor islet isolation outcomes\u2013a multi-centre cohort study","volume":"31","author":"Meier","year":"2018","journal-title":"Transpl. Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1432-2277.2005.00140.x","article-title":"Clinical outcome of cadaveric renal allografts contaminated before transplantation","volume":"18","author":"Sharma","year":"2005","journal-title":"Transpl. Int."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/ajt.12588","article-title":"Human Microbiota Characterization in the Course of Renal Transplantation","volume":"14","author":"Fricke","year":"2014","journal-title":"Am. J. Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1126\/science.aad3503","article-title":"Population-level analysis of gut microbiome variation","volume":"352","author":"Falony","year":"2016","journal-title":"Science"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1126\/science.aad3369","article-title":"Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity","volume":"352","author":"Zhernakova","year":"2016","journal-title":"Science"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.cgh.2015.05.027","article-title":"Patients Receiving Prebiotics and Probiotics Before Liver Transplantation Develop Fewer Infections Than Controls: A Systematic Review and Meta-Analysis","volume":"13","author":"Sawas","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.biopha.2018.12.104","article-title":"Probiotic supplements might not be universally-effective and safe: A review","volume":"111","author":"Kothari","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/jgh3.12093","article-title":"Fecal microbiota transplantation in recurrent Clostridium difficile infection: A retrospective single-center chart review","volume":"3","author":"Kim","year":"2019","journal-title":"JGH Open"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1394379","DOI":"10.1155\/2018\/1394379","article-title":"A systematic review of the efficacy and safety of fecal microbiota transplant for Clostridium difficile infection in immunocompromised patients","volume":"2018","author":"Shogbesan","year":"2018","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1182\/blood-2016-05-717652","article-title":"Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut","volume":"128","author":"Kakihana","year":"2016","journal-title":"Blood"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/10\/672\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:27:35Z","timestamp":1760189255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/10\/672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,4]]},"references-count":97,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["medicina55100672"],"URL":"https:\/\/doi.org\/10.3390\/medicina55100672","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,4]]}}}